Novo Nordisk A/S - Articles of Association

Novo and Hengrui Pharma enter 2.6 billion USD license agreement for obesity and diabetes pill that could potentially be taken only once every week

Bagsværd, Denmark, 28 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...